Back to Journals » Drug Design, Development and Therapy » Volume 13

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study

Total article views   HTML views PDF downloads Totals
8,713 Dovepress* 7,811+ 1,229 9,040
PubMed Central* 902 155 1,057
Totals 8,713 1,384 10,097
*Since 24 January 2019

View citations on PubMed Central and Google Scholar